PMXSF (Syntara) Moat Score: 0/10 (As of Jul. 01, 2026)


PMXSF Syntara Ltd PMXSF
13 GF Score
Price $0.03
! 1 Warning Sign
View Full Analysis

What is Syntara Moat Score?

Syntara has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Syntara has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Syntara might have No Moat - No discernible moat.

Syntara  (OTCPK:PMXSF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Syntara Moat Score Related Terms

PMXSF
13GF Score
Syntara Ltd PMXSF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Syntara Business Description

Other Exchanges UUDA:GermanySNT:Australia
Address 20 Rodborough Road, Unit 2, Frenchs Forest, Sydney, NSW, AUS, 2086
Syntara Ltd is a clinical-stage drug development company working to bring new and life-changing treatments to patients in need. It is targeting extracellular matrix dysfunction with its expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The company has various drug candidates in its pipeline such as SNT-5505, SNT-4728, SNT-5382, and SNT-8370 as a potential treatment for cancer, skin scarring and neuroinflammation.
13GF Score

Get the complete analysis for PMXSF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.03
Price